Atrial Fibrillation as a Prognostic Factor for All-Cause Mortality in Patients With Transthyretin Amyloid Cardiomyopathy

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Atrial Fibrillation in Transthyretin Amyloid Cardiomyopathy: A Marker of Disease Severity but Not an Independent Predictor of Mortality2026 · 1 citations
2. 2Baseline Predictors of Adverse Outcomes for Transthyretin Amyloidosis Cardiomyopathy Patients Treated and Untreated with Tafamidis: A Canadian Referral Center Experience2024 · 1 citations
3. 3Impact of Tafamidis on Transthyretin Concentration and Its Relation to All-Cause Mortality in Patients with Transthyretin Amyloid Cardiomyopathy: An Analysis from ATTR-ACT2026
4. 4Atrial Fibrillation Burden, Risk Factors, and Prognosis in Wild-type Transthyretin Amyloidosis Cardiomyopathy2025 · 4 citations
5. 5Real-world effectiveness of tafamidis in a contemporary, matched cohort of patients with variant and wild-type transthyretin amyloid cardiomyopathy2025